The Official MicroCap News Source
Watchlist News
Please Login or Register to view News Stories

Healthcare & Insurance

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower

Saturday, September 18, 2021

Agra Ventures Announces Change of Auditor

VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (Frankfurt: PU30.F) (OTCPK: AGFAD), a growth-oriented and diversified company focused on the international cannabis industry, announces that it has changed its auditor

Saturday, September 18, 2021

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

Friday, September 17, 2021

Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

SOLANA BEACH, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that the Company’s annual meeting of shareholders, on September 14, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required

Friday, September 17, 2021

Relay & Fio Announce Agreement with Unisys Corp. (NYSE: UIS) to Market a Combined Solution for COVID-19 and Biosecurity Market Needs

TORONTO, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) and Fio Corporation (“Fio”) – together through their joint venture, Fionet Rapid Response Group (“FRR”) – are pleased to announce an agreement

Friday, September 17, 2021

Pasithea Therapeutics Corp. Announces Closing of $24.0 Million Initial Public Offering

MIAMI BEACH, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the

Friday, September 17, 2021

Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the Oppenheimer Fall

Friday, September 17, 2021

Century Therapeutics Announces Its Addition to the Russell 2000® Index

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will be added to the small-cap Russell 2000® Index as a

Friday, September 17, 2021

Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to eight newly hired employees

Friday, September 17, 2021

Aesther Healthcare Acquisition Corp. Announces Closing of Initial Public Offering and Partial Exercise of Over-Allotment Option

New York, NY, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp. (Nasdaq: AEHAU) (the “Company”) announced today the closing of its initial public offering of 10,000,000 units at $10.00 per unit. Each unit consists of one share of the Company’s Class A common stock and

Friday, September 17, 2021

InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021

VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, will report financial results for the fiscal year ended June 30, 2021,

Friday, September 17, 2021

PAOG Confirms Plans For First CBD Nutraceutical Revenue In 2021 Targeting $16 Billion Market

Sandusky, OH, Sept. 17, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today published a brief status update on the company’s ongoing initiatives to include confirming plans to launch a CBD Nutraceuticals line of products expected to generate revenue this year, in 2021. The company

Friday, September 17, 2021

Iba – Acquisition of Own Shares

Immediate Release – September 17th, 2021 Louvain-la-Neuve, Belgium, September 17th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation

Friday, September 17, 2021

Filing of the Groupama 2021 Half Year Financial Report

Groupama announces its Half Year Financial Report for 2021 is now available on its website and has been filed with the French stock exchange regulatory authority, l’Autorité des Marchés Financiers.This document includes the half year 2021 combined financial statements, the half year activity

Friday, September 17, 2021

Director/PDMR Shareholding

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM  1Details of the person discharging managerial responsibilities (PDMR)/person closely associated with them (PCA)a)NameCristina Nestares 2Reason for the

Friday, September 17, 2021

Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce

Cryptocurrency accepted include Bitcoin (BTC), Ethereum (ETH), Dogecoin (DOGE), Bitcoin Cash (BCH) and Litecoin (LTC) New York, NY, and Tel Aviv, ISRAEL, Sept. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a medical diagnostics and solutions company

Friday, September 17, 2021

Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase

WAYNE, Pa. and ROCKVILLE, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet

Friday, September 17, 2021

CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

VUMERITY is a next-generation oral fumarate with a well-characterized efficacy and safety profileData from the Phase 3 EVOLVE-MS-2 study have demonstrated that treatment with VUMERITY results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile Upon approval, VUMERITY

Friday, September 17, 2021

Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board

Loughborough, England, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching

Friday, September 17, 2021

Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine

 Expands GEN-1 Program Collaboration to Add Clinical and Commercial Batches of Investigational Vaccine LAWRENCEVILLE, N.J. and HAINAN, China, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation

Friday, September 17, 2021

loading

© 2021 Stock News Now